More importantly, NIPBL downregulation improved chemotherapy resistance (cisplatin, paclitaxel, gemcitabine hydrochloride) of non-small cell lung cancer cells (Xu et al., 2015). The gene discussed is NIPBL; the disease is non-small cell lung carcinoma.